文献速递神经免疫

利妥昔单抗与继发进展型多发性硬化残疾进展的关联

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2019-01-01

这项回顾性队列研究在瑞士巴塞尔、卢加诺和荷兰阿姆斯特丹的3个多发性硬化中心纳入2004至2017年的继发进展型多发性硬化(SPMS)患者,采用倾向评分匹配比较接受利妥昔单抗治疗者与从未接受利妥昔单抗者的残疾进展。匹配后44对(88例)分析显示,利妥昔单抗组EDSS评分显著更低,确认残疾进展时间显著延迟,提示B细胞清除可能获益,但需前瞻性随机试验证实。

要点

  • 匹配队列中利妥昔单抗组EDSS评分平均差异为-0.52(95%CI -0.79至-0.26,P<.001)。
  • 确认残疾进展时间在利妥昔单抗组显著延迟(HR 0.49,95%CI 0.26-0.93,P=.03)。
  • 结果为回顾性观察,尚不能确立因果,需随机对照试验验证。

核心结论

  • 在SPMS患者中,利妥昔单抗治疗与随访至10年内EDSS评分显著更低及确认残疾进展显著延迟相关,提示B细胞清除可能具有治疗益处。
  • 作者指出需开展证据级别更高的前瞻性随机临床试验以确认利妥昔单抗在该类患者中的疗效。

研究设计与样本

  • 回顾性队列研究,数据来自瑞士巴塞尔、卢加诺和荷兰阿姆斯特丹3个多发性硬化中心,时间范围2004至2017年。
  • 利妥昔单抗组57例符合条件、54例纳入;从未治疗组504例符合条件、59例纳入;纳入需至少1次随访。
  • 采用倾向评分匹配,匹配变量为性别、年龄、EDSS评分和疾病病程;1:1匹配后纳入44对(88例)进行分析。

主要发现

  • 匹配集协变量校正分析中,利妥昔单抗组平均随访3.5(2.7)年期间EDSS评分显著更低,平均差异-0.52(95%CI -0.79至-0.26;P<.001)。
  • 利妥昔单抗组确认残疾进展时间显著延迟,风险比0.49(95%CI 0.26-0.93;P=.03)。
  • 匹配队列基线:利妥昔单抗组平均年龄49.7(10.0)岁、病程18.2(9.4)年、EDSS 5.9(1.4),女性26例(59%);对照组分别为51.3(7.4)岁、19.4(8.7)年、5.70(1.29),女性27例(61%)。

关键数值与推荐

  • 主要终点为基线后EDSS评分进展,次要终点为至确认残疾进展的时间。
  • 随访最长10年;总队列中利妥昔单抗组平均随访3.5(2.6)年、对照组5.4(2.4)年;匹配队列中分别为3.5(2.7)年和4.8(2.2)年。

临床怎么用

  • 对SPMS患者,利妥昔单抗可作为B细胞清除治疗的候选选择,但应结合个体情况并与患者讨论证据的不确定性。
  • 治疗决策不宜仅依据本回顾性结果,需等待前瞻性随机试验提供更高等级证据。

局限性

  • 研究为回顾性队列设计,存在残余混杂可能,无法确立因果关系。
  • 匹配后样本量较小(44对),随访时间在组间不完全均衡,结论需随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Therapeutic options for patients with secondary progressive multiple sclerosis (SPMS) are limited. OBJECTIVE: To analyze disability progression in patients with SPMS treated with rituximab compared with matched control patients never treated with rituximab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study analyzed data obtained from patients with SPMS at 3 multiple sclerosis centers located in Basel and Lugano, Switzerland, and Amsterdam, the Netherlands, from 2004 to 2017. Patients were included for analysis if they had received a diagnosis of SPMS, were treated (57 eligible; 54 included) or never treated (504 eligible; 59 included) with rituximab, and had at least 1 follow-up visit. The variables used for propensity score matching were sex, age, Expanded Disability Status Scale (EDSS) score, and disease duration. Follow-up duration was up to 10 years, with a mean (SD) of 3.5 (2.6) years for rituximab-treated patients and 5.4 (2.4) years for controls in the total cohort and a mean (SD) of 3.5 (2.7) years for rituximab-treated patients and 4.8 (2.2) years for controls in the matched cohort. EXPOSURES: Comparing EDSS score progression in patients with SPMS (treated with rituximab vs not treated with rituximab) using propensity score matching. MAIN OUTCOMES AND MEASURES: The primary end point was progression of EDSS score after baseline, and the secondary end point was time to confirmed disability progression. RESULTS: After 1:1 propensity score matching, 44 matched pairs (88 patients) were included in the analysis. At baseline, patients treated with rituximab had a mean (SD) age of 49.7 (10.0) years, mean (SD) disease duration of 18.2 (9.4) years, and mean (SD) EDSS score of 5.9 (1.4), and 26 (59%) were women, whereas controls had a mean (SD) age of 51.3 (7.4) years, mean (SD) disease duration of 19.4 (8.7) years, and mean (SD) EDSS score of 5.70 (1.29), and 27 (61%) were women. In the covariate-adjusted analysis of the matched set, patients with SPMS who were treated with rituximab had a significantly lower EDSS score during a mean (SD) follow-up of 3.5 (2.7) years (mean difference, -0.52; 95% CI, -0.79 to -0.26; P < .001). Time to confirmed disability progression was significantly delayed in the rituximab-treated group (hazard ratio, 0.49; 95% CI, 0.26-0.93; P = .03). CONCLUSIONS AND RELEVANCE: In this study, patients with SPMS treated with rituximab had a significantly lower EDSS score for up to 10 years of follow-up and a significantly delayed confirmed progression compared with matched controls, suggesting that B-cell depletion by rituximab may be therapeutically beneficial in these patients. A prospective randomized clinical trial with a better level of evidence is needed to confirm the efficacy of rituximab in such patients.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Naegelin Y, Naegelin P, von Felten S, et al. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2019. PMID: 30615019. doi:10.1001/jamaneurol.2018.4239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。